1. FDA Rejects Replimune's Melanoma Drug Again, Cementing Stricter Stance Under New Leadership
The FDA has delivered a second, decisive rejection to Replimune Group's experimental treatment for advanced melanoma, solidifying the therapy's status as a flashpoint in a high-stakes debate over regulatory standards. This engineered virus, designed to activate the immune system against skin cancer, was initially turne...